POLITICS

US supports waiver of Covid-19 vaccine IP restrictions – Cyril Ramaphosa

President says proposal establishes a global solution to enhance manufacturing and boost supply capacity

President Cyril Ramaphosa welcomes US support for waiver of Coronavirus COVID-19 vaccine IP restrictions

6 May 2021

President Cyril Ramaphosa welcomes the support of the United States’ Biden-Harris Administration for a temporary and targeted waiver of intellectual property protections that apply to COVID-19 vaccines.

The United States government announced on Wednesday, 5 May 2021, that the COVID-19 pandemic was a global health crisis which called for extraordinary measures.

The United States said it believed strongly in intellectual property protections. However, in service of ending the pandemic, it would at forthcoming negotiations of the World Trade Organisation (WTO) support the waiver of those protections for COVID-19 vaccines.

President Ramaphosa welcomes the position adopted by the United States as an important reinforcement of a campaign led by South Africa and India on behalf of emerging economies that face vaccine shortages and production challenges.

The anticipated temporary waiver provides a global response to COVID-19. The proposal establishes a global solution to enhance manufacturing and boost supply capacity, and enables coordination and access to information currently under patent protection.

For countries that do not currently have manufacturing capacity on certain medical technologies, the waiver could open up more supply options and avoid countries being reliant on only one or two suppliers. Where supply-capacity currently exists, it can be repurposed to COVID-vaccine production and in this way improve the supply available to all nations.  

President Ramaphosa says the forthcoming WTO negotiations provide the global community, and especially leading economies, with both an opportunity and the challenge to act in the best interest of all humanity.

This can be achieved by focusing on the moral, legal and economic benefits of providing urgent, affordable and equitable protection to all people around the world in the face of a grave and indiscriminate threat to life and economic sustainability.

In light of the growing global consensus, we call on pharmaceutical companies to facilitate sharing of know-how and technology to enable a rapid increase in supply-capacity in order to save lives.

Issued by Tyrone Seale, Acting Spokesperson to the President, 6 May 2021